Patents by Inventor Ronnie C. Mease

Ronnie C. Mease has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150369738
    Abstract: A detectable substrate for aldehyde dehydrogenase (ALDH) can be used for selecting cells that express ALDH. The detectable substrate can have a fluorescent moiety that has an excitation wavelength, an emission wavelength, or both, that does not overlap with the excitation wavelength, emission wavelength, or both, of green fluorescent protein.
    Type: Application
    Filed: February 21, 2014
    Publication date: December 24, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, HAOFAN WANG, IL MINN, STEVEN D. LEACH, RONNIE C. MEASE
  • Publication number: 20150246144
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, CATHERINE ANNE FOSS
  • Patent number: 9044468
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: June 2, 2015
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ray Sangeeta, Ronnie C. Mease, Catherine Foss
  • Publication number: 20150104387
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Application
    Filed: April 2, 2014
    Publication date: April 16, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
  • Publication number: 20140341804
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 20, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin Gilbert Pomper, Sangeeta Ray, Ronnie C. Mease
  • Publication number: 20110200677
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Application
    Filed: November 26, 2008
    Publication date: August 18, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20110064657
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
    Type: Application
    Filed: June 26, 2008
    Publication date: March 17, 2011
    Applicant: The Johns Hopkins University
    Inventors: Martin Gilbert Pomper, Ray Sangeeta, Ronnie C. Mease, Catherine Foss
  • Patent number: 6022522
    Abstract: Bicyclo[2.2.2]octane-2,3 diamine-N,N,N',N'-tetraacetic acids (BODTA) and bicyclo[2.2.1]heptane-2,3 diamine-N,N,N',N'-tetraacetic acid (BHDTA) are chelating agents useful in forming detectably labeled bioconjugate compounds for diagnostic and therapeutic purposes. New compounds and processes of forming BODTA and BHDTA are disclosed. Radioimmunoconjugates of the present invention show high and prolonged tumor uptake with low normal tissue uptakes.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: February 8, 2000
    Assignee: Brookhaven Science Associates
    Inventors: Mark P. Sweet, Ronnie C. Mease, Suresh C. Srivastava
  • Patent number: 5840859
    Abstract: A compound is provided of formula I: ##STR1## wherein n is 4-16, Det is an organic group comprising a radioisotope or capable of chelating a radioisotope, and Z.sup.- is one equivalent of a biologically acceptable anion, which compounds are useful to radiolabel cellular membranes, as of hematopoietic cells.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: November 24, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Carol Lambert, Ronnie C. Mease, John G. McAfee
  • Patent number: 5783169
    Abstract: Bicyclo?2.2.2! octane-2,3 diamine-N,N,N',N'-tetraacetic acids (BODTA) and bicyclo?2.2.1! heptane-2,3 diamine-N,N,N',N'-tetraacetic acid (BHDTA) are chelating agents useful in forming detectably labeled bioconjugate compounds for diagnostic and therapeutic purposes. New compounds and processes of forming BODTA and BHDTA are disclosed. Radioimmunoconjugates of the present invention show high and prolonged tumor uptake with low normal tissue uptakes.
    Type: Grant
    Filed: July 26, 1995
    Date of Patent: July 21, 1998
    Assignee: Brookhaven Science Associates LLC
    Inventors: Mark P. Sweet, Ronnie C. Mease, Suresh C. Srivastava
  • Patent number: 5639879
    Abstract: A simple method for the synthesis of 1,4,7, 10-tetraazacyclododecane N,N'N",N'"-tetraacetic acid and 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"-tetraacetic acid involves cyanomethylating 1,4,7, 10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane to form a tetranitrile and hydrolyzing the tetranitrile. These macrocyclic compounds are functionalized through one of the carboxylates and then conjugated to various biological molecules including monoclonal antibodies. The resulting conjugated molecules are labeled with radiometals for SPECT and PET imaging and for radiotherapy.
    Type: Grant
    Filed: February 2, 1995
    Date of Patent: June 17, 1997
    Assignee: Associated Universities, Inc.
    Inventors: Ronnie C. Mease, Leonard F. Mausner, Suresh C. Srivastava
  • Patent number: 5635157
    Abstract: Cyclohexyl chelating agents useful in forming antibody-metal conjugates useful for diagnostic and therapeutic purposes. New compounds and processes of forming these compounds are disclosed including 4-haloacetamido-trans-1,2-diaminocyclohexyl polyaminocarboxylate and 4-isothiocyanato-trans-1,2-diamino cyclohexane-N, N, N', N'-tetra acetic acid.
    Type: Grant
    Filed: October 6, 1993
    Date of Patent: June 3, 1997
    Inventors: Ronnie C. Mease, Kathryn L. Kolsky, Leonard F. Mausner, Suresh C. Srivastava
  • Patent number: 5428156
    Abstract: A simple method for the synthesis of 1,4,7,10-tetraazacyclododecane N,N'N",N'"-tetraacetic acid and 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"-tetraacetic acid involves cyanomethylating 1,4,7,10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane to form a tetranitrile and hydrolyzing the tetranitrile. These macrocyclic compounds are functionalized through one of the carboxylates and then conjugated to various biological molecules including monoclonal antibodies. The resulting conjugated molecules are labeled with radiometals for SPECT and PET imaging and for radiotherapy.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: June 27, 1995
    Assignee: Associated Universities, Inc.
    Inventors: Ronnie C. Mease, Leonard F. Mausner, Suresh C. Srivastava
  • Patent number: 5334729
    Abstract: The present invention relates to new rigid chelating structures, to methods for preparing these materials, and to their use in preparing radiometal labeled immunoconjugates. These new chelates include cyclohexyl EDTA monohydride, the trans forms of cyclohexyl DTPA and TTHA, and derivatives of these cyclohexyl polyaminocarboxylate materials.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: August 2, 1994
    Assignee: Associated Universities, Inc.
    Inventors: Ronnie C. Mease, Suresh C. Srivastava, Jean-Francois Gestin
  • Patent number: 5292938
    Abstract: Cyclo agents useful in forming antibody-metal conjugates useful for diagnostic and therapeutic purposes. New compounds and processes of forming these compounds are disclosed including 4-haloacetamido-trans-1,2-diaminocyclohexyl polyaminocarboxylate and 4-isothiocyanato-trans-1,2-diamino cyclohexane-N,N,N',N'-tetra acetic acid.
    Type: Grant
    Filed: April 13, 1992
    Date of Patent: March 8, 1994
    Assignee: Associated Universities, Inc.
    Inventors: Ronnie C. Mease, Leonard F. Mausner, Suresh C. Srivastava
  • Patent number: 5089663
    Abstract: The present invention relates to new rigid chelating structures, to methods for preparing these materials, and to their use in preparing radiometal labeled immunoconjugates. These new chelates include cyclohexyl EDTA monohydride, the trans forms of cyclohexyl DTPA and TTHA, and derivatives of these cyclohexyl polyaminocarboxylate materials.
    Type: Grant
    Filed: April 2, 1991
    Date of Patent: February 18, 1992
    Assignee: Associated Universities, Inc.
    Inventors: Ronnie C. Mease, Suresh C. Srivastava, Jean-Francois Gestin
  • Patent number: 5021571
    Abstract: The present invention relates to new rigid chelating structures, to methods for preparing these materials, and to their use in preparing radiometal labeled immunoconjugates. These new chelates include cyclohexyl EDTA monohydride, the transforms of cyclohexyl DTPA and TTHA and derivatives of these cyclohexyl polyaminocarboxylate materials.
    Type: Grant
    Filed: June 29, 1989
    Date of Patent: June 4, 1991
    Assignee: Associated Universities, Inc.
    Inventors: Ronnie C. Mease, Suresh C. Srivastava